Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
Nationwide population-based study (2005 to 2018) of 250 million hospital admissions in Germany reveals changed trends and the course of liver cirrhosis and its complications
Scientists from Goethe University Hospital Frankfurt under leadership of Prof. Jonel Trebicka analyzed the data from the Federal Statistical Office of Germany of around 250 million hospital admissions in Germany from 2005 to 2018 and found out that the number of hospital admissions with cirrhosis has increased nationwide, and its diagnosis as a comorbidity doubles the mortality rate of other chronic diseases.
All results of this nationwide study published in "The Lancet Regional Health - Europe", demonstrate the need for development of strategies to improve care in cirrhosis to decrease this considerable healthcare burden.More news
3rd General Assembly Meeting, Leuven, Belgium
Our first hybrid-GA meeting, taking place from 6-8 October 2021 in Leuven, Belgium has been successfully completed with 37 participants joining on-site, and over 20 participants remotely.
A lot of data has been presented with promising multiomics results to develop biomarkers to predict disease progression and response to treatment for patients suffering from cirrhosis and ACLF.